Last updated: May 28, 2026
BELRAPZO is the brand name for belzutifan. Supply chain visibility for BELRAPZO depends on the specific commercial presentation (tablet strength) and the market (US vs EU). A complete supplier map requires the drug label, FDA product listing, and any BLA manufacturing/supply agreements tied to the belzutifan registration.
If you need a supplier list for business use (licensing, vendor qualification, or litigation risk), the only defensible approach is to enumerate:
- the marketed-drug manufacturing sites listed in the approved labeling and FDA drug registration data for belzutifan tablets,
- the firms designated as “manufactured for” and “distributed by” on the commercial package/labeling,
- the sites named as drug substance and drug product manufacturing in the BLA filing and subsequent supplements, and
- any public batch supply constraints disclosed by the marketing authorization holder.
No such product-specific supplier roster is provided in the available input for BELRAPZO (belzutifan), and without label- and FDA/EU-registration-backed details, producing a supplier list would be incomplete.
What companies supply BELRAPZO (belzutifan) to the US market?
Answer: The US commercial suppliers for BELRAPZO are the drug product manufacturer(s) and the label “distributed by” organization named in the BELRAPZO prescribing information and US FDA product listing for belzutifan tablets.
What does “supplier” mean for BELRAPZO in a supply-chain diligence workflow?
For pharmaceutical diligence, supplier coverage typically splits into three buckets:
- Drug product manufacturer (finished tablets): site(s) that manufacture the belzutifan tablet(s) under the marketing authorization holder.
- Label distributor / marketing authorization holder: entity that appears on labeling as distributor/marketer.
- Drug substance (belzutifan API) suppliers: site(s) that manufacture belzutifan bulk drug substance used by tablet manufacturers.
Which manufacturers make belzutifan API and which sites make BELRAPZO tablets?
Answer: API and tablet sites are defined by the BLA’s manufacturing section and the associated commercial labeling.
How to map API vs drug product suppliers for belzutifan tablets
A correct mapping requires matching:
- FDA registration “manufacturing sites” for the belzutifan product (drug product),
- and BLA manufacturing disclosures for belzutifan drug substance.
What is BELRAPZO’s Orange Book status and what does that imply for supplier risk?
Answer: Orange Book status is not an informative proxy for branded biologics and most oncology targeted small molecules where exclusivity and patents are separate from manufacturing qualification. The key diligence outcome is still the list of manufacturing sites and their change history, not exclusivity alone.
Where supplier changes show up in practice
Even when exclusivity is intact, supplier risk shifts with:
- manufacturing site transfers,
- scale-up or tech transfer validations,
- and FDA inspections tied to the listed sites.
When do BELRAPZO supply disruptions typically occur and who is most exposed?
Answer: Exposure is concentrated at the tablet manufacturing site(s) and the API supply chain for belzutifan. Without the listed manufacturers and API sites, any timeline or exposure allocation cannot be stated.
How do EU marketing authorization supply arrangements for BELRAPZO differ from the US?
Answer: EU supply is governed by the marketing authorization holder and the manufacturing sites listed in the European public assessment dossier (EPAR) and label. The US is governed by FDA registration and labeling and can list different contract manufacturers.
Which suppliers are the key bottlenecks for belzutifan tablet production?
Answer: The bottleneck is the belzutifan API-to-tablet link:
- API manufacturer capacity and yield constraints
- drug product formulation/processing and tablet packaging lines at the finished-site
A supplier bottleneck analysis requires the actual manufacturing site list and site capacity statements, which are not present in the provided input.
Key Takeaways
- BELRAPZO is belzutifan; “supplier” must be defined as drug substance and drug product manufacturing sites plus label-distribution entities.
- A defensible supplier list must come from BELRAPZO’s approved labeling and official FDA/EU product registration manufacturing disclosures.
- The current input does not contain the label/FDA/EU-backed supplier entities needed to produce an accurate supplier roster.
FAQs
- Who is the marketing authorization holder for BELRAPZO in the US?
- What contract manufacturers produce belzutifan tablets under the BELRAPZO label?
- Which sites manufacture belzutifan API used for BELRAPZO?
- Do EU and US supplier sites for BELRAPZO match, or do they differ?
- How can I identify BELRAPZO’s manufacturing sites from public regulatory records?
References
- (No citable source included in the provided input.)
